Cover Story
Regulatory News
By Jacquelyn Cobb and Paul Goldberg
The FDA Oncologic Drugs Advisory Committee voted overwhelmingly in favor of expanding the indications of two chimeric antigen receptor engineered T-cell therapies for multiple myeloma that showed improvement in progression-free survival, but also reported a higher number of early deaths on the experimental arm.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity
- 2024 Karnofsky Award winner Lillian Siu talks about her career in phase I studies, ctDNA, and her mentor’s “evil red pencil”
- Voices of Black women can improve cancer outcomes